middle.news
Actinogen Clears Final Trial Hurdle Ahead of Alzheimer’s Data
8:47am on Wednesday 23rd of September, 2026 AEST
•
Biotechnology
Read Story
Actinogen Clears Final Trial Hurdle Ahead of Alzheimer’s Data
8:47am on Wednesday 23rd of September, 2026 AEST
Key Points
Final patient visit completed in the 247-participant XanaMIA trial
Topline results remain scheduled for November 2026
36-week placebo-controlled study tests Xanamem 10 mg
Primary endpoint is the CDR-SB dementia scale
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE